Neisseria Gonorrhoeae Infection Clinical Trial
— PORTAPHAROfficial title:
Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study
Since the use of antibiotics, Neisseria Gonorrhoeae (NG) has acquired progressive resistance to penicillins, sulfonamides, tetracyclines and quinolones. The oropharynx is recognized as an important site for DNA exchange between NG and other commensal Neisseria, allowing NG to acquire new antimicrobial resistance. Despite the worrying data on the emergence of resistant NG, the recommendations remain to systematically treat these infections with ceftriaxone, including asymptomatic pharyngeal localizations. The objective of our study is to evaluate a ceftriaxone sparing strategy in order to limit the emergence of antibiotic resistance. The primary objective of the study is to evaluate the clearance of Neisseria gonorrhoeae, 3 months after the diagnosis of asymptomatic pharyngeal carriage documented on nucleic acid amplification test (NAAT).
Status | Not yet recruiting |
Enrollment | 254 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Patients (n=154): Patient inclusion criteria : - Adult patient (age = 18 years old) - Patient consulting for a pharyngeal Neisseria gonorrhoeae Sexually Transmitted Infection (STI) and meeting the following criteria : - Positive sample for NAAT by PCR in the pharynx for Neisseria gonorrhoeae dating back a maximum of 7 days (the date of the sample and those of inclusion will be compared) and - asymptomatic patient - Absence of symptoms of other bacterial STIs or other asymptomatic bacterial STIs confirmed on the systematic screening assessment carried out within 7 days before inclusion - Patient's agreement to use protection or abstinence from all oral sex for 3 months follow-up (experimental group) or for 7 days (control group) - For men whose female partner(s) are of childbearing age and for women of childbearing age: use of effective contraception (failure rate less than 1% per year) throughout research - Patient benefiting from a social health security scheme - Patient having signed a free and informed consent Patients non-inclusion criteria : - Minor patient - Symptomatic patient in the pharynx - Presence of symptoms of another bacterial STI or of an asymptomatic bacterial STI confirmed on the screening report carried out within 7 days before inclusion - Antibiotic treatment that may be active on Neisseria gonorrhoeae (C3G, Fluoroquinolones, Macrolides, Cyclins, Aminosides, Penicillins) within 14 days before inclusion - Hypersensitivity to ceftriaxone, other cephalosporins or to any of the excipients - History of severe hypersensitivity (e.g. anaphylactic reaction) to another class of antibacterial agents of the beta-lactam family (penicillins, monobactams and carbapenems). - Contraindication to ceftriaxone - Contraindication to intramuscular injections - Person under legal protection, under guardianship or curatorship, person deprived of liberty, under safeguard of justice, subject to psychiatric care, under duress, admitted to a health or social establishment for purposes other than those of research - Pregnant or breastfeeding woman - Lack of social health insurance - Patient included in another interventional study Partners (n=100) : Partner Inclusion Criteria : - Sexual contact of the index case (genito-anal or genito-vaginal, oro-genital or oro-anal or oro-oral relations) in the month preceding the inclusion of the index case - Adult patient (age = 18 years old) - Patient benefiting from a social health security scheme - Patient having signed a free and informed consent Partner non-inclusion Criteria: - Minor patient - Person under legal protection, under guardianship or curatorship, person deprived of liberty, under safeguard of justice, subject to psychiatric care, under duress, admitted to a health or social establishment for purposes other than those of research - Patient included in another interventional study - Pregnant or breastfeeding woman |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with a negative pharyngeal nucleic acid amplification test (NAAT) for Neisseria gonorrhoeae (NG) | 3 months after inclusion | ||
Secondary | Proportion of patients with a negative pharyngeal nucleic acid amplification test (NAAT) and a negative pharyngeal culture for Neisseria gonorrhoeae (NG) | at 1 month after inclusion | ||
Secondary | Proportion of patients with negative pharyngeal NG cultures | at 3 months after inclusion | ||
Secondary | Proportion of patients carrying methicillin-resistant Staphylococcus aureus (MRSA) | Impact of ceftriaxone on the carriage of methicillin-resistant Staphylococcus aureus (MRSA) on the pharyngeal sample | at 1 month after inclusion | |
Secondary | Proportion of patients carrying extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae | Impact of ceftriaxone on the carriage of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae on the anal sample | at 1 month after inclusion | |
Secondary | Proportion of patients carrying methicillin-resistant Staphylococcus aureus (MRSA) | Impact of ceftriaxone on the carriage of methicillin-resistant Staphylococcus aureus (MRSA) on the pharyngeal sample and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae on the anal sample | at 3 months after inclusion | |
Secondary | Proportion of patients carrying extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae | Impact of ceftriaxone on the carriage of extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae on the anal sample | at 3 months after inclusion | |
Secondary | Proportion of patients with spontaneous pharyngeal clearance of NG | Analysis of factors associated with spontaneous pharyngeal clearance of NG :
Socio-demographic and behavioural characteristics Amount of NG in the pharynx assessed by exploratory semi-quantitative PCR Bactericidal activity of anti-gonococcal antibodies and the production of specific anti-gonococcal antibodies in pharyngeal secretions |
at 1 month after inclusion | |
Secondary | Proportion of patients with spontaneous pharyngeal clearance of NG | Analysis of the factors associated with spontaneous pharyngeal clearance of NG :
Socio-demographic and behavioural characteristics Amount of NG in the pharynx assessed by exploratory semi-quantitative PCR Bactericidal activity of anti-gonococcal antibodies and the production of specific anti-gonococcal antibodies in pharyngeal secretions |
at 3 months after inclusion | |
Secondary | Proportion of partners with NAAT positive for NG | Proportion of partners with NAAT positive for NG on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) | At inclusion of the partner | |
Secondary | Proportion of partners with NG cultures positive | Proportion of partners with NG cultures positive on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) | At inclusion of the partner | |
Secondary | Proportion of partners with NAAT positive for NG | Proportion of partners with NAAT positive for NG on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) | at 1 month after inclusion of the partner | |
Secondary | Proportion of partners with NG cultures positive | Proportion of partners with NG cultures positive on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) | at 1 month after inclusion of the partner | |
Secondary | Proportion of partners with NAAT positive for NG | Proportion of partners with NAAT positive for NG on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) | at 3 months after inclusion of the partner | |
Secondary | Proportion of partners with NG cultures positive | Proportion of partners with NG cultures positive on at least one of the three sites of infection (pharyngeal, anal, first-void urine or vaginal self-sampling) | at 3 months after inclusion of the partner | |
Secondary | Proportion of identical genome between partner and patient | Up to 3 months | ||
Secondary | Proportion of patients with Resistant NG strains | Up to 3 months | ||
Secondary | Proportion of partners with Resistant NG strains | Up to 3 months | ||
Secondary | Proportion of adverse events | Up to 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04269434 -
GonoScreen: Efficacy of Screening STIs in MSM
|
N/A | |
Completed |
NCT04094883 -
Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine
|
Phase 4 | |
Completed |
NCT01733069 -
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHERâ„¢ System
|
N/A | |
Completed |
NCT00978848 -
Non-Invasive Sexually Transmitted Disease Testing in Women Seeking Emergency Contraception or Urine Pregnancy Testing
|
N/A | |
Recruiting |
NCT05286931 -
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
|
N/A | |
Completed |
NCT01329588 -
Periodical Presumptive Treatment for the Control of Gonococcal Infections Among Sex Workers
|
Phase 4 | |
Not yet recruiting |
NCT06369220 -
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
|
N/A | |
Completed |
NCT05216744 -
Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection
|
Phase 2 | |
Recruiting |
NCT05581160 -
Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)
|
N/A | |
Completed |
NCT02870101 -
Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT
|
N/A |